Search

Your search keyword '"Duan,Zhongping"' showing total 757 results

Search Constraints

Start Over You searched for: Author "Duan,Zhongping" Remove constraint Author: "Duan,Zhongping"
757 results on '"Duan,Zhongping"'

Search Results

201. Impact of metabolic risk factors on the severity and outcome of patients with alcohol‐associated acute‐on‐chronic liver failure.

202. Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure

203. Application of CRISPR/Cas9 system in virus research

209. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China

210. Sofosbuvir/Velpatasvir for Treatment of Hepatitis C Virus in Asia: An Open-Label, Phase 3 Study

213. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

215. Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis, Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia.

216. M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes.

217. Cathepsin H-Mediated Degradation of HDAC4 for Matrix Metalloproteinase Expression in Hepatic Stellate Cells: Implications of Epigenetic Suppression of Matrix Metalloproteinases in Fibrosis through Stabilization of Class IIa Histone Deacetylases.

219. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure

220. Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release

221. M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes

225. Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis, Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia

226. Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis (NASH), Obesity,and Metabolic Disorders in an Animal Model by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia

227. Cathepsin H–Mediated Degradation of HDAC4 for Matrix Metalloproteinase Expression in Hepatic Stellate Cells

230. The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication

231. Nationwide survey of specialist knowledge on current standard of care (Peg‐IFN/RBV) and barriers of care in chronic hepatitis C patients in China

232. Vitamin D Signaling through Induction of Paneth Cell Defensins Maintains Gut Microbiota and Improves Metabolic Disorders and Hepatic Steatosis in Animal Models

235. Innovation for hepatotoxicity in vitro research models: A review.

236. Chinese guidelines on the management of ascites and its related complications in cirrhosis.

237. Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure.

238. A bioelectrical impedance phase angle measuring system for assessment of nutritional status

241. Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge

242. Persistence of cirrhosis is maintained by intrahepatic regulatory T cells that inhibit fibrosis resolution by regulating the balance of tissue inhibitors of metalloproteinases and matrix metalloproteinases

245. Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure

247. Persistently Increased Resting Energy Expenditure Predicts Short-Term Mortality in Patients with Acute-on-Chronic Liver Failure.

248. Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release.

249. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

250. The Inhibition of Glycogen Synthase Kinase 3 beta Ameliorates Liver Ischemia Reperfusion Injury via an IL-10-mediated Immune Regulatory Mechanism

Catalog

Books, media, physical & digital resources